Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VC005 in Severe Alopecia Areata
NCT07749716Phase 2Recruiting
- Sponsor
- Jiangsu Vcare PharmaTech Co., Ltd.
- Start
- Aug 2026
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of VC-005 in alopecia areata (3 arms), sponsored by Jiangsu Vcare PharmaTech Co., Ltd. Primary endpoint: Proportion of subjects with a Severity of Alopecia Tool (SALT) score ≤ 20 at 24 weeks. Started Aug 2026; status: recruiting.
02
Drugs
VC-005
03
Conditions
alopecia areata
Beyond the preview
Go deeper on NCT07749716.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07749716.